Articles tagged with Lymphoma
Researchers discovered that tumors in lymph nodes are distinct from solid tumors, with a unique pattern of branching and signaling pathways. They identified VEGF-C as the primary driver of angiogenesis in early stages of lymphoma, which can be targeted to slow tumor growth.
A new study reveals that MNT is required for the survival of MYC-driven lymphoma cells, suggesting a promising new approach for treating this type of cancer. Inhibiting MNT may also make tumours more susceptible to other drugs, offering hope for improved treatments.
A randomized, double-blind trial compared the safety and efficacy of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma. F14512 demonstrated significant antitumor activity and clinical benefits, particularly in P-glycoprotein overexpressing lymphomas.
A new analysis reveals that donor stem cell transplantation following PD-1 treatment is generally safe and produces good outcomes for patients with Hodgkin lymphoma. Post-transplant treatment with cyclophosphamide may also lead to improved results, reducing rates of acute GVHD and relapse.
A new study from Georgetown University Medical Center found that 38 patients with follicular lymphoma who were in remission for at least two years did not show any evidence of the disease in their blood. This suggests that these patients may be disease-free and could have a lifelong disease status.
Researchers discovered that chronic inflammatory processes in aging brains lead to lymphoma cells being retained in the brain tissue instead of being released back into the blood. The NF-kappaB signaling pathway and CCL19 play a crucial role in this process, allowing lymphoma cells to multiply and develop tumors.
Follicular lymphoma originates from mutations in RagC gene on mTOR signalling pathway, affecting B cell growth. Rapamycin treatment delays progression and prolongs survival in mice with RagC mutations.
A study found a statistically significant association between BRCA2 mutations and increased risk of non-Hodgkin lymphoma in children. Additionally, BRCA2 mutations were not associated with an increased risk of Hodgkin lymphoma.
Researchers at UNC Lineberger Comprehensive Cancer Center discovered a hyperactive cell signal contributing to tumor growth in aggressive blood cancer. They developed an experimental therapeutic compound, UNC3810A, that targeted and slowed tumor growth by blocking the hyperactive Tyro3 protein.
Researchers discovered MYC's new roles in cancer cell efficiency and protein production. High MYC levels stimulate specific mRNAs translation into respiratory complex proteins, fueling growth. This study reveals MYC regulates metabolic enzymes and immune receptors in lymphoma cells.
Researchers from Johns Hopkins Medicine found a distinct subtype of primary central nervous system lymphoma suitable for surgical removal, offering improved outcomes and potential cure rates. The study suggests a shift in treatment approach, moving away from traditional biopsy, radiotherapy, and high-dose chemotherapy.
Researchers identified LTA as a key player in Hodgkin's lymphoma progression, activating NF-kB and promoting cancer cell proliferation. This discovery suggests LTA could be a target for new treatment strategies.
Researchers from Colorado State University found that dogs with omega-3 fatty acid supplements or hypothyroidism are less likely to develop T-zone lymphoma. The study also revealed a link between defective genes and the disease, suggesting potential new avenues for research and prevention.
Early results from the UNITY-NHL phase II clinical trial show umbralisib to be highly active against relapsed/refractory marginal zone lymphoma, with a 55% partial or complete response rate and 71% progression-free survival at 12 months.
A Phase II trial at MD Anderson Cancer Center showed umbralisib to be an effective treatment for patients with relapsed marginal zone lymphoma, achieving a 55% partial or complete response rate. The drug was well-tolerated, with a 71% progression-free survival after one year.
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a distinct form of cancer linked to textured breast implants. Clear guidelines formalize treatment strategy, recommending surgical techniques like stepwise en bloc resection for complete oncologic resection and removal of involved lymph nodes.
Survivors of childhood Hodgkin lymphoma are at a significantly increased risk of developing various types of solid tumors over the long term. Certain subgroups of patients have an even higher risk, and these findings may help refine guidelines for cancer screening in Hodgkin lymphoma survivors.
The Paul G. Allen Frontiers Group has awarded $13.5 million to 10 researchers studying lymphoma, neuroimmunology, nuclear biophysics, and brain cell function. These studies aim to shed light on Alzheimer's disease and develop new treatments for blood cancers.
A phase III trial shows duvelisib significantly extends progression-free survival, offering a new treatment option for patients with relapsed or treatment-resistant CLL and SLL. The therapy also works well in sub-group analyses for hardest-to-treat cases with limited options.
Researchers have developed a new drug that targets EBV-positive tumors and inhibits tumor development and metastases for EBV-related lymphomas. The findings suggest the drug may be useful in treating malignancies in EBV-positive patients.
Researchers at Georgia State University have developed a blood test that can diagnose two types of cancer, lymphoma and melanoma, using mid-infrared spectroscopy. The test has shown promising results in differentiating between healthy mice and those with tumorous conditions, and could potentially be used for screening humans.
Researchers found that higher physical activity prior to diagnosis and increased activity after diagnosis significantly improved overall and lymphoma-specific survival. Decreased perception of physical activity also led to poorer outcomes.
A new study identifies six genetic changes linked to Hodgkin lymphoma, a cancer of the immune system. The research offers important clues for understanding both lymphoma and autoimmune diseases.
A Cancer Research UK-funded study found that combining anti-CD27 and anti-CD20 antibodies increases life expectancy in mice with cancer by nearly doubling the median survival time. The combination recruits more immune cells and enhances their ability to destroy cancer cells, offering a promising new approach to treating lymphoma.
The University of Iowa/Mayo Clinic Lymphoma SPORE is one of the nation's longest-standing programs, funded for five years at $12.4 million. The team conducts translational and clinical studies to develop new approaches to lymphoma prevention, detection, and treatment.
Researchers discovered that the Sestrin1 gene is frequently missing or malfunctioning in follicular lymphoma patients, leading to tumor growth and poor prognosis. The study found that targeting this gene can suppress tumors and improve treatment efficacy, offering hope for new therapies.
Cancer researchers at GW Cancer Center investigate how mantle cell lymphoma cells develop resistance to targeted therapy Ibrutinib. They found that the cells adapt by activating alternative pathways, such as PI3K-AKT-mTOR, allowing them to continue progressing.
Research found that Hodgkin lymphoma survivors who received chest irradiation had significantly more multi-vessel coronary artery disease and higher segment involvement scores compared to controls. The study suggests that patients should be screened for coronary artery disease at regular intervals after irradiation.
Researchers at Osaka University discovered how specific genes regulate B cell cycling in germinal centers. They found that Foxo1 promotes B cell proliferation, but its activation is associated with lymphomas. Reviving BATF levels recovered the proliferation of Foxo1-deficient B cells.
Scientists have discovered that GSK3 plays a crucial role in controlling B cell metabolism, adapting to varying energy needs. The study found that GSK3 limits metabolic activity in circulating B cells while slowing glycolysis and production of mitochondria in proliferating B cells in germinal centers.
Researchers uncover disparate evolutionary trajectories and mutational profiles driving follicular lymphoma's transformation and early progression. The study highlights key genes and biological processes associated with these events, offering a basis for future research on prognostic assays and treatment strategies.
Researchers found GALV retrovirus was likely transmitted to gibbons from rodents by medical researchers working on human diseases, causing a serious outbreak in the 1960s and 1970s. No evidence of ongoing infection or threat found in current captive gibbon populations.
HIV-infected patients with chronic HBV and HCV coinfection are at a higher risk for non-Hodgkin's lymphoma, a leading cause of AIDS-related deaths. The study found that the incidence rate is 10 times higher in HIV-infected persons compared to the general population.
A large-scale migrant cohort study found that being born in Israel significantly increases the risk of nodular sclerosis HL, with elevated risks also observed among women, those born more recently, and taller stature. The study suggests exposure to unidentified elements of the Israeli environment may contribute to the disease's etiology.
Researchers have developed a new approach to limit side effects of stem cell transplants by stimulating the formation of regulatory T cells in recipients. Pretreating mice with STAR2 protein protected them from developing GvHD, while donor-derived cells retained their ability to kill recipient's tumor cells.
Researchers at Université de Genève have developed an antibody that blocks the migration of cancer cells, preventing their spread and proliferation. The 'H225' antibody reduces cancerous cell transit into organs by over 50% and limits cell proliferation, offering a promising new therapeutic strategy against lymphoma.
Researchers developed a measurement called cumulative burden to capture chronic disease in childhood cancer survivors, showing that Hodgkin lymphoma patients have more cardiovascular conditions and severe heart problems than adults without childhood cancer. This method should aid efforts to reduce and better manage late effects of canc...
A Phase II trial suggests that brentuximab vedotin can cure some patients with Hodgkin lymphoma who have relapsed despite previous therapies. The study reports that 13 of 34 patients who achieved complete remission remained disease-free for over five years.
A UCLA study found that anti-inflammatory gut bacteria can slow or stop the development of certain types of cancer. Researchers discovered that a specific bacterium, Lactobacillus johnsonii 456, reduced gene damage and inflammation in mice with cancer, leading to a lower risk of tumor formation.
A new study reveals significant racial disparities in treatment for patients with HIV and Hodgkin lymphoma, with black patients facing higher rates of non-treatment. Despite effective treatment options, doctors note that socioeconomic factors and lack of access to care may contribute to these disparities.
Mutations in follicular lymphoma have revealed new molecular targets for potential treatments, according to researchers at Queen Mary University of London. The mutations identified allow tumours to evade normal restrictions on growth, making existing therapies less effective.
Researchers analyzed data from 6039 Hodgkin's lymphoma survivors, finding a higher risk of cardiovascular disease associated with specific dose levels of radiation and anthracycline exposure.
A combination of lenalidomide and rituximab produced a durable response in mantle cell lymphoma patients, with an overall response rate of 92%. The treatment maintained an anti-tumor response for up to three years.
Researchers found that overcrowded conditions protect against developing a particular type of Hodgkin lymphoma, while female patients in the 20-24 age group have a higher incidence rate. The study also suggests that oestrogens may be responsible for this increased risk.
A recent study by Rockefeller University researchers has uncovered the connection between malaria and a deadly blood cancer called Burkitt's lymphoma, which predominantly affects children in equatorial Africa. The research found that the malaria parasite causes DNA damage in B lymphocytes, leading to cancer-promoting changes.
The trial showed that early FDG-PET-positive patients benefit from intensification of chemotherapy, leading to improved progression-free survival rates. However, omitting involved-node radiotherapy in early PET-negative patients did not demonstrate non-inferiority to the standard treatment in terms of progression-free survival.
Researchers at the University of Rochester Medical Center have identified a subgroup of follicular lymphoma patients who experience early disease recurrence despite modern treatments. These patients may require personalized therapy approaches, such as targeted sequencing or gene-expression profiling, to improve their outcomes.
Survivors of Hodgkin lymphoma have a persistently increased risk of cardiovascular disease throughout life, with a cumulative risk of 50% at 40 years after diagnosis. The study found that mediastinal radiotherapy and anthracycline-containing chemotherapy significantly increased the risks of cardiovascular events.
New research suggests that persistent swollen lymph glands in the neck are a high-risk indicator for lymphoma. By referring patients with unexplained swollen neck glands for further investigation, doctors can help reduce cancer-related deaths in the UK.
A UK National Cancer Research Institute trial suggests that a PET scan after chemotherapy can identify patients who don't need additional radiotherapy, reducing late effects. The study found that 90.8% of patients without further treatment remained disease-free compared to 94.6% in the radiotherapy group.
Researchers identify JAK/STAT3 cell signaling pathway as driver of ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin's lymphoma. Compounds targeting this pathway show promise in inhibiting disease progression, offering new hope for effective treatments.
A committee of lymphoma experts identified key priority areas in infrastructure and research to advance treatments. The Roadmap for Discovery and Translation in Lymphoma outlines priorities to improve understanding of lymphoma biology across diverse subtypes.
A phase 3 trial shows that brentuximab vedotin significantly increases progression-free survival in adults with hard-to-treat Hodgkin lymphoma. The drug was found to be well-tolerated, with side effects including peripheral neuropathy and neutropenia.
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of 3D computed tomography-based radiation therapy planning and volumetric image guidance to treat pediatric Hodgkin lymphoma. The guidelines aim to reduce radiation dose to normal tissue and decrease the risk of late side effects.
Researchers found a mutated region in human mantle cell lymphoma DNA that disables programmed cell death. Cells with this mutation grow uncontrollably, but a new therapy approach targets the ubiquitin ligase responsible for the defect.
Researchers present new advances in treating relapsed and treatment-resistant lymphoma, including targeted therapies and stem cell transplantation, to improve patient outcomes. These studies show promising results for patients with HIV-associated lymphoma, where traditional treatments have been limited.
A late-stage clinical trial demonstrated that brentuximab vedotin can improve progression-free survival and overall survival in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant. The study showed a 20% improvement in progression-free survival rate and high response rates among patients.
A £600,000 grant from Cancer Research UK will fund a research study investigating the efficacy of BTK inhibiting drugs in treating mantle cell lymphoma. The trial will compare these new drugs to standard chemotherapy and aim to improve life expectancy and quality of life for patients.
A promising anti-cancer approach targeting Malt1 protein's protease function in lymphoma cells may also cause destructive autoimmune inflammation when its other functions are preserved. Researchers discovered this unexpected side effect using an animal model, emphasizing the need for new alternatives to treat lymphomas.
Two patients with cardiac lymphoma presented with brain metastasis, highlighting the need for identifying prognostic factors that predict brain relapse. Cardiac lymphoma is a rare condition often overlooked due to its potential for central nervous system metastasis.